Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.


Journal

Schizophrenia (Heidelberg, Germany)
ISSN: 2754-6993
Titre abrégé: Schizophrenia (Heidelb)
Pays: Germany
ID NLM: 9918367987006676

Informations de publication

Date de publication:
21 03 2022
Historique:
received: 04 05 2021
accepted: 11 02 2022
entrez: 22 3 2022
pubmed: 23 3 2022
medline: 23 3 2022
Statut: epublish

Résumé

While research focus remains mainly on psychotic symptoms, it is questionable whether we are placing enough emphasis on improving the quality of life (QoL) of schizophrenia patients. To date, the predictive power of QoL remained limited. Therefore, this study aimed to accurately predict the QoL within schizophrenia using supervised learning methods. The authors report findings from participants of a large randomized, double-blind clinical trial for schizophrenia treatment. Potential predictors of QoL included all available and non-redundant variables from the dataset. By optimizing parameters, three linear LASSO regressions were calculated (N = 697, 692, and 786), including 44, 47, and 41 variables, with adjusted R-squares ranging from 0.31 to 0.36. Best predictors included social and emotion-related symptoms, neurocognition (processing speed), education, female gender, treatment attitudes, and mental, emotional, and physical health. These results demonstrate that machine learning is an excellent predictive tool to process clinical data. It appears that the patient's perception of their treatment has an important impact on patients' QoL and that interventions should consider this aspect.Trial registration: ClinicalTrials.gov Identifier: NCT00014001.

Identifiants

pubmed: 35314708
doi: 10.1038/s41537-022-00236-w
pii: 10.1038/s41537-022-00236-w
pmc: PMC8938459
doi:

Banques de données

ClinicalTrials.gov
['NCT00014001']

Types de publication

Journal Article

Langues

eng

Pagination

29

Informations de copyright

© 2022. The Author(s).

Références

Nurs Health Sci. 2017 Jun;19(2):142-148
pubmed: 27109014
Int Rev Psychiatry. 2010;22(5):417-28
pubmed: 21047156
J Clin Epidemiol. 2018 Nov;103:131-133
pubmed: 30063954
Psychiatr Serv. 2003 Apr;54(4):565-7
pubmed: 12663847
Schizophr Res. 2013 Jul;147(2-3):275-80
pubmed: 23693066
Actas Esp Psiquiatr. 2012 Jan-Feb;40(1):10-8
pubmed: 22344491
J Nerv Ment Dis. 2009 May;197(5):311-5
pubmed: 19440103
Schizophr Res. 1990 Jul-Aug;3(4):247-51
pubmed: 2278986
Perspect Psychiatr Care. 2019 Apr;55(2):147-152
pubmed: 29578605
Psychol Med. 1998 May;28(3):551-8
pubmed: 9626712
Schizophr Bull. 1990;16(2):293-307
pubmed: 2374885
Schizophr Bull. 2007 Sep;33(5):1225-37
pubmed: 17204532
Am J Health Promot. 1996 Nov-Dec;11(2):87-98
pubmed: 10163601
Schizophr Bull. 2003;29(1):15-31
pubmed: 12908658
Neuropsychiatr Dis Treat. 2015 May 28;11:1371-9
pubmed: 26064055
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Can J Psychiatry. 1997 Mar;42(2):139-51
pubmed: 9067063
Qual Life Res. 2019 Jun;28(6):1509-1520
pubmed: 30805880
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:8-18
pubmed: 30552914
Acta Psychiatr Scand. 2000 Oct;102(4):303-9
pubmed: 11089732
Am J Psychiatry. 2008 Aug;165(8):978-87
pubmed: 18450928
Psychiatry Res. 2018 Oct;268:392-399
pubmed: 30125870
Annu Rev Clin Psychol. 2018 May 7;14:91-118
pubmed: 29401044
Schizophr Bull. 1984;10(3):388-98
pubmed: 6474101
Psychiatry Res. 2004 Dec 15;129(2):141-7
pubmed: 15590041
Dialogues Clin Neurosci. 2007;9(2):215-26
pubmed: 17726919
Compr Psychiatry. 2017 May;75:94-102
pubmed: 28342379
J Am Psychiatr Nurses Assoc. 2017 Nov/Dec;23(6):404-413
pubmed: 28569084
BMC Psychiatry. 2013 Jan 09;13:15
pubmed: 23302219
Psychiatr Q. 2019 Sep;90(3):519-532
pubmed: 31119453
Psychiatry Clin Neurosci. 2008 Aug;62(4):404-11
pubmed: 18778437
PLoS One. 2015 Aug 14;10(8):e0135267
pubmed: 26275139
Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Mar;3(3):223-230
pubmed: 29486863
J Clin Psychiatry. 2005 Mar;66(3):331-8
pubmed: 15766299
CNS Drugs. 2009 Aug;23(8):649-59
pubmed: 19594194
JAMA Psychiatry. 2018 Nov 1;75(11):1156-1172
pubmed: 30267047
Am J Psychiatry. 2007 Dec;164(12):1791-802
pubmed: 18056233
Psychiatry J. 2020 Aug 31;2020:5848601
pubmed: 32934955
Psicothema. 2017 May;29(2):160-165
pubmed: 28438236

Auteurs

Mélissa Beaudoin (M)

Centre de Recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada. Melissa.Beaudoin.1@UMontreal.ca.
Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, Canada. Melissa.Beaudoin.1@UMontreal.ca.
Faculty of Medicine, McGill University, Montreal, Canada. Melissa.Beaudoin.1@UMontreal.ca.

Alexandre Hudon (A)

Centre de Recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.
Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, Canada.

Charles-Edouard Giguère (CE)

Centre de Recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.

Stéphane Potvin (S)

Centre de Recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada.
Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, Canada.

Alexandre Dumais (A)

Centre de Recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada. Alexandre.Dumais@UMontreal.ca.
Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, Canada. Alexandre.Dumais@UMontreal.ca.
Institut National de Psychiatrie Légale Philippe-Pinel, Montreal, Canada. Alexandre.Dumais@UMontreal.ca.

Classifications MeSH